Personalized Cancer
Detection is made to order
With SimpleScreen™, you can now help more patients access screening that reflects their individual risks and needs, all through a simple blood draw.
(GettyImages-1441726130)
of cancers are detected by screening3
Too many eligible patients remain unscreened
We know when cancer is found early, it is more treatable. Yet fewer than 1 in 5 individuals eligible for lung cancer screening are up to date with low-dose CT screening.1 And only 3 in 5 eligible individuals 45+ years are up to date with guideline-recommended colorectal screening.2
The challenge isn't choosing between today's screening approaches and tomorrow's. It’s about finding practical ways to accommodate eligible patients’ differing risks and personal factors so that they can successfully participate in screening.
You can help expand screening participation
Healthcare providers play a pivotal role in helping increase screening participation, but it takes more than new options. It requires a new approach: one that is personalized, evidence-based, and fits into routine care.
Personalized Cancer Detection
Freenome's approach to blood-based cancer screening combines risk-based screening with indication-specific tests from one blood draw.
Guideline-supported testing
The category of blood-based cancer screenings is now included as an additional option for diseases such as Colorectal Cancer.4
(GettyImages-2215510429)
How it works
With the SimpleScreen portfolio, you can select one or more tests that are relevant to each patient, all of which can be completed with one blood draw. Plus, Freenome’s integrated EHR tools make ordering and follow-up easy for you and your team.
Move cancer screening forward for your patients and your practice
Personalized Cancer Detection and Freenome Digital Health are designed to help providers address three persistent challenges in cancer screening:
Help each patient get testing personalized to them
SimpleScreen Lung
Laboratory-developed blood-based screening for adults 50-80 years old with at least a 20 pack-year smoking history.
Performance:84.7% sensitivity, 50% specificity.5
Interpretation:A positive result may indicate the presence of lung cancer and should be followed by a low-dose CT scan (LDCT).
SimpleScreen CRC
FDA-approved blood-based screening for adults 45+ at average risk for colorectal cancer.
Performance:81.1% sensitivity, 90.4% specificity.6,7
Interpretation:A positive result may indicate colorectal cancer or a precancerous lesion; follow with colonoscopy.
Expanding Portfolio
The SimpleScreen portfolio of blood-based tests will continue to expand, with plans to add up to 7+ future indications.
All supported by Freenome Digital Health
EHR-native digital tools that can help providers identify eligible patients, engage patients and care teams, and integrate screening into routine care.
Adopting a new approach may help more patients screen
Join us in shaping what’s next in cancer screening with Personalized Cancer Detection.
References
1. Ezenwankwo E, Yell N, Eberth JM. Lung cancer screening in the United States, 2024: a National Health Interview Survey analysis. Chest. 2025. doi:10.1016/j.chest.2025.11.036
2. Bandi P et al. Cancer Epidemiol Biomarkers Prev. 2025;34(6):836-849.
3. NORC at the University of Chicago. (2022). Percent of Cancers Detected by Screening in the U.S. Available at https://cancerdetection.norc.org
4. American Cancer Society. Colorectal Cancer Guideline | How Often to Have Screening Tests. American Cancer Society; 2024. Accessed August 11, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html
5. Shapira O et al. Cancer Res. 2026;86(7_Supplement):1107-1107.
6. Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer. JAMA. 2025;334(1):56-63. doi:10.1001/jama.2025.7515.
7. Shaukat A, Meng Z, Kutnik K, et al. Age- and sex-adjusted performance of a colorectal cancer screening test using US census distribution. J Natl Cancer Inst. Published online January 9, 2026:djag007. doi:10.1093/jnci/djag007
The SimpleScreen™ CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit. SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Precaution: Based on data from clinical studies, SimpleScreen CRC has limited detection (57%) of Stage I colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy.
© 2026 Freenome, LLC. SimpleScreen Lung has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Freenome’s Clinical Laboratory is CAP accredited, and certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. The following are trademarks of Freenome, LLC: FREENOME®, SimpleScreen™, SimpleScreen logo™, and PREEMPT CRC®. All rights reserved. FRNM-09-2026-0029